# Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

> **NCT05594342** · PHASE3 · UNKNOWN · sponsor: **The Young Investigator Group of Cardiovascular Research** · enrollment: 200 (estimated)

## Conditions studied

- Heart Failure
- Cardiogenic Shock
- Ischemic Heart Disease

## Interventions

- **DRUG:** Ivabradine 7.5Mg Tab
- **DRUG:** DOBUTamine Injectable Solution

## Key facts

- **NCT ID:** NCT05594342
- **Lead sponsor:** The Young Investigator Group of Cardiovascular Research
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2022-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594342, "Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05594342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*